Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapies for cancer, and its news flow reflects both scientific progress and capital markets activity. On this APVO news page, readers can follow company-issued updates and third-party coverage related to its immune-oncology pipeline and corporate developments.
Aptevo’s recent press releases highlight key milestones for mipletamig, its CD123 x CD3 T-cell engager in the RAINIER Phase 1b/2 trial for frontline acute myeloid leukemia. News items include reports of remission rates in early cohorts, safety observations such as the absence of cytokine release syndrome in frontline patients treated to date in reported cohorts, and presentations of data at major medical meetings like the American Society of Hematology (ASH).
Investors and clinicians can also track announcements on Aptevo’s expanding CD3-engaging portfolio, including bispecific candidates APVO442 (PSMA x CD3) for prostate cancer and APVO455 (Nectin-4 x CD3) for multiple solid tumor types, as well as trispecific candidates APVO451 and APVO452 that combine tumor targeting, T-cell activation, and CD40-mediated costimulation. News coverage often details preclinical data presented at scientific conferences such as the Society for Immunotherapy of Cancer (SITC).
In addition to R&D and clinical trial updates, APVO news includes quarterly financial results, descriptions of its cash runway, and disclosures about equity financings, including at-the-market offerings, registered direct offerings, and an equity line of credit structure. Regulatory and governance developments, such as reverse stock split implementation, Nasdaq compliance updates, and amendments to rights agreements, are also reported.
By reviewing the APVO news feed, readers can monitor how Aptevo communicates progress on its ADAPTIR and ADAPTIR-FLEX platform-derived candidates, its interactions with the capital markets, and its participation in scientific and industry conferences.
- 5 out of 6 patients in RAINIER trial achieved remission within 30 days - No cytokine release syndrome (CRS) observed in current trial - One patient achieved complete remission with MRD-negative status - Cohort 2 enrollment completed, Cohort 3 now enrolling
The drug has been tested in nearly 100 patients across three clinical studies, showing promising results in both combination and monotherapy settings. In monotherapy trials, 36% of evaluable patients who failed prior treatments showed significant leukemic blast reduction. The company plans multiple data readouts in 2025.
Aptevo Therapeutics (NASDAQ: APVO) provided an update on APVO711, their preclinical-stage bispecific therapeutic candidate. APVO711 is designed with a dual mechanism that combines PD-L1 checkpoint inhibition with CD40 immune activation, developed using their proprietary ADAPTIR® platform technology.
The company's lead candidate mipletamig continues to show strong efficacy and safety results in AML trials. APVO711 demonstrates promising preclinical results with potential applications across various solid tumors, particularly those resistant to conventional checkpoint therapies. The therapeutic aims to achieve deeper and more sustained responses through its innovative dual-mechanism approach.
Applied Materials (AMAT) has announced it will release its fiscal second quarter 2025 financial results on May 15, 2025.
Aptevo Therapeutics (Nasdaq: APVO), a clinical-stage biotechnology company, has completed its previously announced registered direct offering, raising $2.0 million through the sale of 2,324,000 shares of common stock at $0.862 per share.
The offering was conducted at-the-market under Nasdaq rules, with Roth Capital Partners serving as the exclusive placement agent. The company plans to utilize the net proceeds for continued clinical development of its product candidates, working capital, and general corporate purposes.
The offering was made through a shelf registration statement on Form S-3 (File No. 333-284969) previously filed with the SEC. Aptevo specializes in developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies.
Aptevo Therapeutics (Nasdaq: APVO), a clinical-stage biotechnology company specializing in immune-oncology therapeutics, has announced a $2.0 million registered direct offering of common stock. The company will sell 2,324,000 shares at $0.862 per share, with the offering expected to close around April 22, 2025.
Roth Capital Partners is serving as the exclusive placement agent. The proceeds will support clinical development of product candidates, working capital, and general corporate purposes. The offering is being conducted under an existing shelf registration statement on Form S-3 previously filed with the SEC.
Aptevo Therapeutics (Nasdaq: APVO) has closed its previously announced registered direct offering and concurrent private placement, raising gross proceeds of $2.1 million. The offering consisted of 1,764,710 common stock shares and warrants to purchase up to 3,529,420 shares at a combined price of $1.19 per share and accompanying warrant.
The warrants have an exercise price of $1.19 per share, will be exercisable upon stockholder approval, and expire 5 years from approval date. Roth Capital Partners served as the exclusive placement agent. The company plans to use proceeds for clinical development of product candidates, working capital, and general corporate purposes.
Additionally, Aptevo amended existing warrants from December 12, 2024, reducing their exercise price from $9.53 to $1.19 per share for up to 1,647,088 shares, subject to stockholder approval.
Aptevo Therapeutics (Nasdaq:APVO) has announced a $2.1 million registered direct offering and concurrent private placement priced at $1.19 per share. The offering includes 1,764,710 shares of common stock and warrants to purchase up to 3,529,420 additional shares.
The warrants will have an exercise price of $1.19 per share, becoming exercisable upon shareholder approval and expiring 5 years from the initial exercise date. Roth Capital Partners is serving as the exclusive placement agent.
The company plans to use the proceeds for clinical development of product candidates, working capital, and general corporate purposes. Additionally, Aptevo will amend previously issued warrants from December 12, 2024, reducing their exercise price from $9.53 to $1.19 per share for 1,647,088 shares.
Aptevo Therapeutics (NASDAQ:APVO) reported positive interim results from its RAINIER dose optimization trial for mipletamig in treating frontline AML patients. Two additional patients achieved remission within 30 days of treatment, bringing the total success rate to 9 out of 10 frontline patients across two trials.
The triplet combination of mipletamig + venetoclax + azacitidine achieved a 90% overall remission rate in frontline patients, significantly outperforming the 66% benchmark for the doublet therapy (venetoclax + azacitidine). The complete remission rate of 70% also surpasses the 36% rate from the Viale-A Pivotal trial.
In Cohort 2, which uses an 18mcg dosage level, three patients have been evaluated: two achieved remission within 30 days, while one progressed and passed away for unrelated reasons. Notably, no Cytokine Release Syndrome has been observed in the RAINIER trial, and all patients who achieved remission remain in remission.
Aptevo Therapeutics (NASDAQ:APVO) has provided an overview of APVO603, a novel bispecific antibody in preclinical development for solid tumor treatment. The drug targets 4-1BB and OX40 receptors to enhance anti-tumor immune responses.
Preclinical studies demonstrate that APVO603:
- Enhances T cell and NK cell proliferation
- Maintains favorable safety profile
- Inhibits immune exhaustion
- Shows robust anti-tumor response
The company also updated on other pipeline developments:
- Mipletamig: Phase 1b/2 RAINIER trial showing 100% remission in Cohort 1 within 30 days
- ALG.APV-527: Phase 1 trial for solid tumors showing 59% stable disease rate in 17 evaluable patients
Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotechnology company specializing in immuno-oncology therapeutics with proprietary ADAPTIR® and ADAPTIR-FLEX® platforms, has announced its participation in two major industry conferences this March.
The company will attend the 37th Annual Roth Conference from March 16-18, 2025, in Dana Point, CA, where they will engage in a fireside chat with analyst Jonathan Aschoff. The conference will feature one-on-one meetings, fireside chats, and industry panels, hosting executives from approximately 450 growth sector companies.
Additionally, Aptevo will participate in the Bio-Europe Springtime Partnering Event from March 17-19, 2025, in Milan, Italy. This event is expected to gather nearly 4,000 attendees, focusing on fostering relationships between biotechnology and biopharmaceutical companies.